Swiss longevity biotech company Timeline (parent company Amazentis) announced that it has raised CHF 56 million (US$ 66 million) in an oversubscribed Series D financing round that included strategic investments by L’Oréal and Nestlé.
A placebo-controlled, randomised clinical trial has indicated that urolithin A supplementation has a positive impact on skeletal muscle performance and mitochondrial health among an older population.
Only about 40% of people may have the gut microbes to convert ellagitannins from pomegranate into urolithin A, an ingredient positioned for boosting mitochondrial and muscle function, but direct supplementation with the compound overcomes these individual...
